- Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed regular trading session at $47.90.
- Century Therapeutics (NASDAQ:IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies. Century Therapeutics shares traded as high as 4.55 percent, in a range of $10.28 to $11.5 on day volume of 463.24 thousand shares versus three months average volume of 111.37 thousand shares, closed regular trading session at $10.96.
